Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197806 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT02197806 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 65 participants.
The verdict
NCT02197806, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).
Interventions
- DRUG AGN-199201 Vehicle
- DRUG AGN-199201
- DRUG AGN-190584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197806
The ClinicalTrials.gov registry entry for NCT02197806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AGN-199201 Vehicle is the first listed.
NCT02197806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02197806 about?
NCT02197806 is a clinical study titled "Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia". A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).
What is the current status of trial NCT02197806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2014-07. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02197806?
The interventions under investigation include: AGN-199201 Vehicle (DRUG), AGN-199201 (DRUG), AGN-190584 (DRUG).
Who is sponsoring clinical trial NCT02197806?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.